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COMMENTARY
Mesenchymal stem cells to augment therapeutic
angiogenesis in hind-limb ischemia models:
how important is their source?
Garry P Duffy* and Caroline C Herron
See related research by da Cunha et al., http://stemcellres.com/content/4/4/86
Abstract
Murine models of hind-limb ischemia are frequently
used to assess interventions aimed at improving
therapeutic angiogenesis in critical limb ischemia.
Much of the current focus of angiogenesis lies with
mesenchymal stem cells (MSCs). Important
considerations when using these models include the
strain of mouse, because some strains recover from
ischemia more rapidly than others, and the MSC
source. MSCs derived from certain strains generate
increased levels of growth factors such as vascular
endothelial growth factor. This may significantly affect
the limb’s ability to generate collateral vessels.
Atherosclerotic peripheral arterial disease is common, and
critical limb ischemia (CLI) represents the end stage of
this disease. Although the numbers of peripheral arterial
disease patients progressing to CLI are low, there is a high
morbidity and mortality associated with CLI and patients
suffering from the condition have a poor quality of life.
Therapeutic angiogenesis using stem cells and other
biotherapeutics for the treatment of CLI is still under in-
vestigation. The authors of this study discuss the inherent
variations in the ability of two different mouse strains,
BALB/c and C57/BL6, to recover from ischemia [1].
C57/BL6 mice have a greater density of pre-existing col-
lateral vessels, a higher rate of angiogenesis and increased
expression of vascular endothelial growth factor and
tumor necrosis factor alpha compared with other mouse
strains [2]. These mice therefore have been shown to dem-
onstrate a better recovery from ischemia [3]. This observa-
tion led the authors to question whether mesenchymal
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stem cells (MSCs) generated from different mouse strains
would lead to different levels of recovery from ischemia.
Choosing the appropriate mouse strain is therefore
important not only when determining which strain to use
in a hind-limb ischemia model but also when considering
from which strain to source the MSCs. Use of MSCs has
been at the forefront of investigations into therapeutic
angiogenesis and they have shown promising in vitro [4]
and in vivo [5] results.
Bone marrow cells were collected from the tibia and
femur of 8-week-old BALB/c mice and C57/BL6 mice.
BALB/c mice at 10 to 12 weeks old had ischemia induced
surgically via removal of the femoral artery and closure of
its branches. Five days postoperatively, the thigh muscles
were exposed and 5×105 cells were injected into the quad-
riceps muscle. Aside from positive and negative controls,
animals were divided into groups that received MSCs
obtained from BALB/c mice or MSCs obtained from
C57/BL6 mice (n = 6). The study ran for 35 days, during
which period the degree of ischemia was assessed visually
and scored accordingly. Isometric muscle force was
compared in the gastrocnemius muscles prior to the con-
clusion of the study. Histological analysis assessed muscle
regeneration and fibrosis, and immunohistochemistry
assessed the presence of smooth muscle cells and endo-
thelium. Due to the abovementioned factors, MSCs from
C57/BL6 mice were expected to show greater improve-
ments in angiogenesis and therefore greater benefit in the
treatment of limb ischemia than MSCs derived from
BALB/c mice. Indeed, during cell culture the MSCs
derived from the C57/BL6 mice showed a higher growth
rate and higher vascular endothelial growth factor
expression.
The optimum time point for injection of proangiogenic
factors has not been adequately defined, with most
authors reporting immediate injection into the muscles
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upon ligation of the vessels [6]. In this study, however, the
authors describe poor outcomes with this technique and
therefore injection was delayed until day 5. Further inves-
tigation and analysis in this area is required. Comparison
of the ischemic limbs visually illustrated that 16.7% of the
animals in the treatment groups developed grade II
necrosis. This contrasts with the untreated group, where
approximately 70% reached grade IV necrosis. This differ-
ence suggests the efficacy of MSCs as a treatment option
for limb ischemia. Histological analysis revealed no differ-
ences between the two treatment groups, but both showed
increased muscle regeneration and vessel density when
compared with the nontreatment groups.
Whilst there was no objective measurement of limb
perfusion throughout the study and no differences were
noted between treatment groups, this study nonetheless
raises important questions both with regard to the timing
of treatment post-creation of ischemia in murine models
and with regard to the origin of MSCs. In view of the fact
that there is a clear clinical need for novel treatment
options in the subgroup of patients who are unsuitable for
the traditional methods of revascularization in critical
limb ischemia, and given the interest in MSCs as a poten-
tial treatment for ischemia, we feel further investigation
into the optimum source for deriving MSCs for use in
these models is warranted, and a concerted effort should
be made to find agreement on the optimal model to use
for future assessment of novel therapeutics.
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